Strimvelis® (autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human adenosine deaminase [ADA] cDNA sequence): first case of lymphoid T cell leukaemia after insertional oncogenesis.

Summary:

•    Lymphoid T cell leukemia has been reported in a patient with ADA-SCID 4.7 years after treatment with Strimvelis. 
•    This first case of a hematological malignancy following treatment with Strimvelis is considered to be due to insertional oncogenesis.
•    Patients should be monitored long term, with at least annual visits for the first 11 years and then at 13- and 15-years post treatment with Strimvelis and include a complete blood count with differential, biochemistry and thyroid stimulating hormone.